Skip to main content
Top
Published in: Journal of Translational Medicine 1/2017

Open Access 01-12-2017 | Research

Data-driven interdisciplinary mathematical modelling quantitatively unveils competition dynamics of co-circulating influenza strains

Authors: Bin-Shenq Ho, Kun-Mao Chao

Published in: Journal of Translational Medicine | Issue 1/2017

Login to get access

Abstract

Background

Co-circulation of influenza strains is common to seasonal epidemics and pandemic emergence. Competition was considered involved in the vicissitudes of co-circulating influenza strains but never quantitatively studied at the human population level. The main purpose of the study was to explore the competition dynamics of co-circulating influenza strains in a quantitative way.

Methods

We constructed a heterogeneous dynamic transmission model and ran the model to fit the weekly A/H1N1 influenza virus isolation rate through an influenza season. The construction process started on the 2007–2008 single-clade influenza season and, with the contribution from the clade-based A/H1N1 epidemiological curves, advanced to the 2008–2009 two-clade influenza season. Pearson method was used to estimate the correlation coefficient between the simulated epidemic curve and the observed weekly A/H1N1 influenza virus isolation rate curve.

Results

The model found the potentially best-fit simulation with correlation coefficient up to 96% and all the successful simulations converging to the best-fit. The annual effective reproductive number of each co-circulating influenza strain was estimated. We found that, during the 2008–2009 influenza season, the annual effective reproductive number of the succeeding A/H1N1 clade 2B-2, carrying H275Y mutation in the neuraminidase, was estimated around 1.65. As to the preceding A/H1N1 clade 2C-2, the annual effective reproductive number would originally be equivalent to 1.65 but finally took on around 0.75 after the emergence of clade 2B-2. The model reported that clade 2B-2 outcompeted for the 2008–2009 influenza season mainly because clade 2C-2 suffered from a reduction of transmission fitness of around 71% on encountering the former.

Conclusions

We conclude that interdisciplinary data-driven mathematical modelling could bring to light the transmission dynamics of the A/H1N1 H275Y strains during the 2007–2009 influenza seasons worldwide and may inspire us to tackle the continually emerging drug-resistant A/H1N1pdm09 strains. Furthermore, we provide a prospective approach through mathematical modelling to solving a seemingly unintelligible problem at the human population level and look forward to its application at molecular level through bridging the resolution capacities of related disciplines.
Appendix
Available only for authorised users
Literature
1.
3.
go back to reference Longini IM Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004;159:623–33.CrossRefPubMed Longini IM Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004;159:623–33.CrossRefPubMed
4.
go back to reference Patel R, Longini IM Jr, Halloran ME. Finding optimal vaccination strategies for pandemic influenza using genetic algorithms. J Theor Biol. 2005;234(2):201–12.CrossRefPubMed Patel R, Longini IM Jr, Halloran ME. Finding optimal vaccination strategies for pandemic influenza using genetic algorithms. J Theor Biol. 2005;234(2):201–12.CrossRefPubMed
5.
go back to reference Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature. 2005;437(7056):209–14.CrossRefPubMed Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature. 2005;437(7056):209–14.CrossRefPubMed
6.
go back to reference Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci. 2006;103(15):5935–40.CrossRefPubMedPubMedCentral Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci. 2006;103(15):5935–40.CrossRefPubMedPubMedCentral
8.
go back to reference Halloran ME, Ferguson NM, Eubank S, Longini IM Jr, Cummings DA, Lewis B, Xu S, Fraser C, Vullikanti A, Germann TC, et al. Modeling targeted layered containment of an influenza pandemic in the United States. Proc Natl Acad Sci. 2008;105(12):4639–44.CrossRefPubMedPubMedCentral Halloran ME, Ferguson NM, Eubank S, Longini IM Jr, Cummings DA, Lewis B, Xu S, Fraser C, Vullikanti A, Germann TC, et al. Modeling targeted layered containment of an influenza pandemic in the United States. Proc Natl Acad Sci. 2008;105(12):4639–44.CrossRefPubMedPubMedCentral
9.
go back to reference Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013;98(2):174–85.CrossRefPubMed Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013;98(2):174–85.CrossRefPubMed
10.
go back to reference Mai LQ, Wertheim HFL, Duong TN, van Doorn HR, Hien NT, Horby P. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med. 2010;362:86–7.CrossRef Mai LQ, Wertheim HFL, Duong TN, van Doorn HR, Hien NT, Horby P. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med. 2010;362:86–7.CrossRef
11.
go back to reference Storms AD, Gubareva LV, Su S, Wheeling JT, Okomo-Adhiambo M, Pan CY, Reisdorf E, St George K, Myers R, Wotton JT, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010–11. Emerg Infect Dis. 2012;18(2):308–11.CrossRefPubMedPubMedCentral Storms AD, Gubareva LV, Su S, Wheeling JT, Okomo-Adhiambo M, Pan CY, Reisdorf E, St George K, Myers R, Wotton JT, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010–11. Emerg Infect Dis. 2012;18(2):308–11.CrossRefPubMedPubMedCentral
12.
go back to reference Lackenby A, Moran Gilad J, Pebody R, Miah S, Calatayud L, Bolotin S, Vipond I, Muir P, Guiver M, McMenamin J, et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro Surveill. 2011;16:1–6. Lackenby A, Moran Gilad J, Pebody R, Miah S, Calatayud L, Bolotin S, Vipond I, Muir P, Guiver M, McMenamin J, et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro Surveill. 2011;16:1–6.
13.
go back to reference Hurt AC, Chotpitayasunondh T, Cox NJ, Daniels R, Fry AM, Gubareva LV, Hayden FG, Hui DS, Hungnes O, Lackenby A, et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis. 2012;12:240–8.CrossRefPubMed Hurt AC, Chotpitayasunondh T, Cox NJ, Daniels R, Fry AM, Gubareva LV, Hayden FG, Hui DS, Hungnes O, Lackenby A, et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis. 2012;12:240–8.CrossRefPubMed
14.
go back to reference Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Gehrig N, Kelso A. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med. 2011;365:2541–2.CrossRefPubMed Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Gehrig N, Kelso A. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med. 2011;365:2541–2.CrossRefPubMed
15.
go back to reference Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, Lee RT, Iannello P, Gehrig N, Shaw R, et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis. 2012;206(2):148–57.CrossRefPubMedPubMedCentral Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, Lee RT, Iannello P, Gehrig N, Shaw R, et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis. 2012;206(2):148–57.CrossRefPubMedPubMedCentral
16.
go back to reference Meijer A, Jonges M, van Beek P, Swaan CM, Osterhaus AD, Daniels RS, Hurt AC, Koopmans MP. Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012. Euro Surveill. 2012;17:1–7. Meijer A, Jonges M, van Beek P, Swaan CM, Osterhaus AD, Daniels RS, Hurt AC, Koopmans MP. Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012. Euro Surveill. 2012;17:1–7.
17.
go back to reference Takashita E, Kiso M, Fujisaki S, Yokoyama M, Nakamura K, Shirakura M, Sato H, Odagiri T, Kawaoka Y, Tashiro M. Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013–2014 influenza season in Japan. Antimicrob Agents Chemother. 2015;59(5):2607–17.CrossRefPubMedPubMedCentral Takashita E, Kiso M, Fujisaki S, Yokoyama M, Nakamura K, Shirakura M, Sato H, Odagiri T, Kawaoka Y, Tashiro M. Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013–2014 influenza season in Japan. Antimicrob Agents Chemother. 2015;59(5):2607–17.CrossRefPubMedPubMedCentral
18.
go back to reference Ampofo WK, Al Busaidy S, Cox NJ, Giovanni M, Hay A, Huang S, Inglis S, Katz J, Mokhtari-Azad T, Peiris M, et al. Strengthening the influenza vaccine virus selection and development process: outcome of the 2nd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at the Centre International de Conferences (CICG) Geneva, Switzerland, 7 to 9 December 2011. Vaccine. 2013;31(32):3209–21.CrossRefPubMed Ampofo WK, Al Busaidy S, Cox NJ, Giovanni M, Hay A, Huang S, Inglis S, Katz J, Mokhtari-Azad T, Peiris M, et al. Strengthening the influenza vaccine virus selection and development process: outcome of the 2nd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at the Centre International de Conferences (CICG) Geneva, Switzerland, 7 to 9 December 2011. Vaccine. 2013;31(32):3209–21.CrossRefPubMed
19.
go back to reference Yang JR, Lin YC, Huang YP, Su CH, Lo J, Ho YL, Yao CY, Hsu LC, Wu HS, Liu MT. Reassortment and mutations associated with emergence and spread of oseltamivir-resistant seasonal influenza A/H1N1 viruses in 2005–2009. PLoS ONE. 2011;6(3):e18177.CrossRefPubMedPubMedCentral Yang JR, Lin YC, Huang YP, Su CH, Lo J, Ho YL, Yao CY, Hsu LC, Wu HS, Liu MT. Reassortment and mutations associated with emergence and spread of oseltamivir-resistant seasonal influenza A/H1N1 viruses in 2005–2009. PLoS ONE. 2011;6(3):e18177.CrossRefPubMedPubMedCentral
20.
go back to reference Liu CH, Wang JL, Su CP, Chuang JH, Chang CH, Lai MS. Oseltamivir use and outcomes during the 2009 influenza A H1N1 pandemic in Taiwan. BMC Public Health. 2013;13:646–53.CrossRefPubMedPubMedCentral Liu CH, Wang JL, Su CP, Chuang JH, Chang CH, Lai MS. Oseltamivir use and outcomes during the 2009 influenza A H1N1 pandemic in Taiwan. BMC Public Health. 2013;13:646–53.CrossRefPubMedPubMedCentral
21.
go back to reference Shih SR, Chen GW, Yang CC, Yang WZ, Liu DP, Lin JH, Chiu SC, Chen HY, Tsao KC, Huang CG, et al. Laboratory-based surveillance and molecular epidemiology of influenza virus in Taiwan. J Clin Microbiol. 2005;43(4):1651–61.CrossRefPubMedPubMedCentral Shih SR, Chen GW, Yang CC, Yang WZ, Liu DP, Lin JH, Chiu SC, Chen HY, Tsao KC, Huang CG, et al. Laboratory-based surveillance and molecular epidemiology of influenza virus in Taiwan. J Clin Microbiol. 2005;43(4):1651–61.CrossRefPubMedPubMedCentral
22.
go back to reference Jian JW, Chen GW, Lai CT, Hsu LC, Chen PJ, Kuo SH, Wu HS, Shih SR. Genetic and epidemiological analysis of influenza virus epidemics in Taiwan during 2003 to 2006. J Clin Microbiol. 2008;46(4):1426–34.CrossRefPubMedPubMedCentral Jian JW, Chen GW, Lai CT, Hsu LC, Chen PJ, Kuo SH, Wu HS, Shih SR. Genetic and epidemiological analysis of influenza virus epidemics in Taiwan during 2003 to 2006. J Clin Microbiol. 2008;46(4):1426–34.CrossRefPubMedPubMedCentral
23.
go back to reference Wallinga J, Teunis P, Kretzschmar M. Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. Am J Epidemiol. 2006;164(10):936–44.CrossRefPubMed Wallinga J, Teunis P, Kretzschmar M. Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. Am J Epidemiol. 2006;164(10):936–44.CrossRefPubMed
25.
go back to reference Shaman J, Pitzer VE, Viboud C, Grenfell BT, Lipsitch M. Absolute humidity and the seasonal onset of influenza in the continental United States. PLoS Biol. 2010;8(2):e1000316.CrossRefPubMedPubMedCentral Shaman J, Pitzer VE, Viboud C, Grenfell BT, Lipsitch M. Absolute humidity and the seasonal onset of influenza in the continental United States. PLoS Biol. 2010;8(2):e1000316.CrossRefPubMedPubMedCentral
26.
go back to reference World Health Organization. Pandemic influenza risk management. WHO Interim Guidance. Geneva: World Health Organization; 2013. World Health Organization. Pandemic influenza risk management. WHO Interim Guidance. Geneva: World Health Organization; 2013.
27.
go back to reference Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press; 1991. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press; 1991.
28.
go back to reference Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 2004;103(1–2):133–8.CrossRefPubMed Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 2004;103(1–2):133–8.CrossRefPubMed
29.
go back to reference Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol. 1986;24:157–60.PubMedPubMedCentral Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol. 1986;24:157–60.PubMedPubMedCentral
30.
go back to reference Levy A, Sullivan SG, Tempone SS, Wong KL, Regan AK, Dowse GK, Effler PV, Smith DW. Influenza vaccine effectiveness estimates for Western Australia during a period of vaccine and virus strain stability, 2010 to 2012. Vaccine. 2014;32(47):6312–8.CrossRefPubMed Levy A, Sullivan SG, Tempone SS, Wong KL, Regan AK, Dowse GK, Effler PV, Smith DW. Influenza vaccine effectiveness estimates for Western Australia during a period of vaccine and virus strain stability, 2010 to 2012. Vaccine. 2014;32(47):6312–8.CrossRefPubMed
31.
go back to reference Moldoveanu Z, Clements ML, Prince SJ, Murphy BR, Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine. 1995;13:1006–12.CrossRefPubMed Moldoveanu Z, Clements ML, Prince SJ, Murphy BR, Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine. 1995;13:1006–12.CrossRefPubMed
32.
go back to reference Diekmann O, Heesterbeek JAP. Mathematical epidemiology of infectious diseases: model building, analysis and interpretation. Chichester: Wiley; 2000. Diekmann O, Heesterbeek JAP. Mathematical epidemiology of infectious diseases: model building, analysis and interpretation. Chichester: Wiley; 2000.
33.
go back to reference Dorigatti I, Cauchemez S, Ferguson NM. Increased transmissibility explains the third wave of infection by the 2009 H1N1 pandemic virus in England. Proc Natl Acad Sci. 2013;110:13422–7.CrossRefPubMedPubMedCentral Dorigatti I, Cauchemez S, Ferguson NM. Increased transmissibility explains the third wave of infection by the 2009 H1N1 pandemic virus in England. Proc Natl Acad Sci. 2013;110:13422–7.CrossRefPubMedPubMedCentral
34.
go back to reference Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, Marshall SA, St. George K, Epperson S, Brammer L, Klimov AI, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA. 2009;301:1034–41.CrossRefPubMed Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, Marshall SA, St. George K, Epperson S, Brammer L, Klimov AI, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA. 2009;301:1034–41.CrossRefPubMed
35.
go back to reference Meijer A, Lackenby A, Hungnes O, Lina B, Van Der Werf S, Schweiger B, Opp M, Paget J, Van De Kassteele J, Hay A, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007–08 season. Emerg Infect Dis. 2009;15(4):552–60.CrossRefPubMedPubMedCentral Meijer A, Lackenby A, Hungnes O, Lina B, Van Der Werf S, Schweiger B, Opp M, Paget J, Van De Kassteele J, Hay A, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007–08 season. Emerg Infect Dis. 2009;15(4):552–60.CrossRefPubMedPubMedCentral
36.
go back to reference Bouvier NM, Rahmat S, Pica N. Enhanced mammalian transmissibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase. J Virol. 2012;86(13):7268–79.CrossRefPubMedPubMedCentral Bouvier NM, Rahmat S, Pica N. Enhanced mammalian transmissibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase. J Virol. 2012;86(13):7268–79.CrossRefPubMedPubMedCentral
37.
go back to reference Hurt AC. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol. 2014;8:22–9.CrossRefPubMed Hurt AC. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol. 2014;8:22–9.CrossRefPubMed
38.
go back to reference Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science. 2010;328(5983):1272–5.CrossRefPubMedPubMedCentral Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science. 2010;328(5983):1272–5.CrossRefPubMedPubMedCentral
39.
40.
go back to reference Petrie SM, Butler J, Barr IG, McVernon J, Hurt AC, McCaw JM. Quantifying relative within-host replication fitness in influenza virus competition experiments. J Theor Biol. 2015;382:259–71.CrossRefPubMed Petrie SM, Butler J, Barr IG, McVernon J, Hurt AC, McCaw JM. Quantifying relative within-host replication fitness in influenza virus competition experiments. J Theor Biol. 2015;382:259–71.CrossRefPubMed
Metadata
Title
Data-driven interdisciplinary mathematical modelling quantitatively unveils competition dynamics of co-circulating influenza strains
Authors
Bin-Shenq Ho
Kun-Mao Chao
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2017
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-017-1269-6

Other articles of this Issue 1/2017

Journal of Translational Medicine 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.